fenofibrate PBC
Selected indexed studies
- New Treatment Paradigms in Primary Biliary Cholangitis. (Clin Gastroenterol Hepatol, 2023) [PMID:36809835]
- Primary biliary cholangitis: Personalizing second-line therapies. (Hepatology, 2025) [PMID:39707635]
- PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. (J Transl Autoimmun, 2023) [PMID:36684809]
_Worker-drafted node — pending editorial review._
Connections
fenofibrate PBC is a side effect of
Sources
- New Treatment Paradigms in Primary Biliary Cholangitis. (2023) pubmed
- Primary biliary cholangitis: Personalizing second-line therapies. (2025) pubmed
- PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. (2023) pubmed
- Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial. (2023) pubmed
- Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. (2022) pubmed
- Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions? Authors' reply. (2016) pubmed
- GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate. (2025) pubmed
- Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions? (2016) pubmed
- PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. (2025) pubmed
- Fibrates and cholestasis. (2015) pubmed